Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...
Optimistic Buy Rating for Gain Therapeutics’ GT-02287 Based on Promising Parkinson’s Disease Treatment Potential
Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
bovnews14h
What’s Behind the 3.59% Gain in Heron Therapeutics Inc (HRTX) Stock? Find Out Now!
Heron Therapeutics Inc (HRTX) stock saw a modest uptick, ending the day at $2.02 which represents a slight increase of $0.07 or 3.59% from the prior close of $1.95. The stock opened at $1.99 and ...
bovnews17h
What’s Fueling Dyne Therapeutics Inc (DYN) Stock’s 27.37% Gain Above Its 200-Day SMA?
Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $36.41 which represents a slight increase of $2.07 or 6.03% from the prior close of $34.34. The stock opened at $35.06 and ...
Zevra Therapeutics: A Strong Buy on Miplyffa’s Approval and Market Potential
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Zevra Therapeutics (ZVRA – Research Report) today and set a price target ...
Why Applied Therapeutics Stock Is Skyrocketing Today
Shares of Applied Therapeutics (NASDAQ: APLT) had skyrocketed 70.5% as of 10:43 a.m. ET on Wednesday. The huge gain came after the U.S. Food and Drug Administration (FDA) told the company that an ...
Investing1d
Gain Therapeutics Inc (GANX)
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunctionBETHESDA, Md., March 05, 2024 (GLOBE NEWSWIRE) ...
TG Therapeutics Inc (TGTX): Short Seller Sentiment is Bearish
We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
Foghorn Therapeutics Inc. (FHTX) shares rallied 9.5% in the last trading session to close at $9.72. This move can be attributable to notable volume with a higher number of shares being traded than in ...
Here's Why Everyone's Talking About Summit Therapeutics
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
PYC Therapeutics has a market capitalisation of AU$677m and burnt through AU$39m last year, which is 5.7% of the company's market value. That's a low proportion, so we figure the company would be able ...